Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 7/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | CLK2 | P49760 | 2/20 | 0.37 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.37 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | ROS1 | P08922 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FER | P16591 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2091922 | 0.88 | NPC1 (0.43) | NPC1RAB9ABRD4ADORA3KDR | |
| SCHEMBL647637 | 0.87 | SMN1; SMN2 (0.44) | NPC1RAB9ABRD4ADORA3KDR | |
| SCHEMBL5139714 | 0.86 | BRD4 (0.39) | BRD4ADORA3KDRCLK2HIPK4 | |
| SCHEMBL646761 | 0.86 | ADORA3 (0.46) | NPC1RAB9ABRD4ADORA3KDR | |
| SCHEMBL10124519 | 0.84 | RXRA (0.42) | NPC1RAB9ABRD4ADORA3RXRA | |
| SCHEMBL646580 | 0.84 | DEGS1 (0.45) | NPC1RAB9AADORA3DYRK1AMEN1 | |
| SCHEMBL648071 | 0.83 | MAPT (0.44) | NPC1RAB9ARXRAPPARGNR1H3 | |
| SCHEMBL646895 | 0.83 | HPGDS (0.41) | NPC1RAB9ARXRAALDH1A1MAPT | |
| SCHEMBL647037 | 0.83 | ABL1 (0.52) | NPC1RAB9AADORA3MAPTKMT2A | |
| SCHEMBL647082 | 0.83 | BRD4 (0.43) | BRD4RXRAPPARGNR1H3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614321-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8119643-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119643-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119643-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | IL5, CXCR5, NLRP3 | NPC1 852/4885RAB9A 3009/4885BRD4 521/4885 |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | IL5, CXCR5, NLRP3 | NPC1 852/4885RAB9A 3009/4885BRD4 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.